Ivabradine Chanelle Medical

Ivabradine, the active ingredient in Ivabradine Chanelle Medical, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adults.

GNH USA supplies Ivabradine Chanelle Medical as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to lower heart rate in several cardiovascular conditions. - Chronic stable angina: improves exercise tolerance by reducing myocardial oxygen demand. - Heart failure with reduced ejection fraction: decreases hospitalization risk through sustained heart‑rate control. - Patients intolerant to beta‑blockers: provides heart‑rate reduction without beta‑adrenergic blockade.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Bradycardia: heart rate falls below the intended therapeutic range. - Visual disturbances (phosphenes): transient luminous phenomena, especially at the start of therapy. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Nausea.

Serious or Rare Side Effects: - Symptomatic bradycardia leading to syncope. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Hepatic enzyme elevation. - Visual impairment persisting beyond initial exposure. - Allergic reactions such as rash or angio‑edema.

Before initiating ivabradine, clinicians should consider several safety measures. - Cardiac monitoring: obtain baseline ECG and heart‑rate assessment. - Concomitant beta‑blockers: avoid excessive heart‑rate reduction. - Severe hepatic impairment: use with caution and consider dose adjustment. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Renal impairment: monitor renal function and adjust dose if required. - Store at room temperature: keep in the original container, protect from moisture and light.

Ivabradine interacts with several medicines that affect its plasma concentration or heart‑rate response.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Concomitant bradycardic agents (beta‑blockers, digoxin, diltiazem): risk of excessive bradycardia.

Moderate Interactions (Monitor Closely): - Calcium‑channel blockers (verapamil, diltiazem): may raise plasma concentration; monitor heart rate. - Diuretics: electrolyte shifts can influence cardiac rhythm; observe patient closely.